1. Home
  2. ARVN vs MHD Comparison

ARVN vs MHD Comparison

Compare ARVN & MHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$9.20

Market Cap

516.2M

Sector

Health Care

ML Signal

HOLD

Logo Blackrock MuniHoldings Fund Inc.

MHD

Blackrock MuniHoldings Fund Inc.

HOLD

Current Price

$11.54

Market Cap

604.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
MHD
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
516.2M
604.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ARVN
MHD
Price
$9.20
$11.54
Analyst Decision
Buy
Analyst Count
19
0
Target Price
$15.05
N/A
AVG Volume (30 Days)
878.8K
283.2K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
N/A
4.16%
EPS Growth
58.84
N/A
EPS
1.70
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.28
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.96
$10.99
52 Week High
$14.22
$12.08

Technical Indicators

Market Signals
Indicator
ARVN
MHD
Relative Strength Index (RSI) 64.01 48.58
Support Level $7.90 $11.61
Resistance Level $9.65 $11.78
Average True Range (ATR) 0.40 0.10
MACD 0.07 0.02
Stochastic Oscillator 75.50 64.41

Price Performance

Historical Comparison
ARVN
MHD

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About MHD Blackrock MuniHoldings Fund Inc.

Blackrock Muniholdings Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes. The fund mainly invests its managed assets in municipal bonds rated investment grade or, if unrated, are deemed to be of comparable quality by the investment adviser at the time of investment. Its investment portfolio is mainly comprised of long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.

Share on Social Networks: